Introduction
Dendritic cells (DC) constantly sample their environment and present captured antigens to T cells in the secondary lymphoid compartment (1) . Presentation of innocuous antigens captured under steady-state conditions leads to tolerance, whilst antigen presentation in the context of infection results in the priming of naïve T cells (2) . The conversion of DC from tolerogenic to immunogenic during infection is thought to depend on their capacity to sense pathogen components or damage associated with disease (2) . DC recognize infectious agents and their products using an array of receptors, including Toll-like receptors (TLR), C-type lectin-like receptors, retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), nucleotidebinding oligomerisation domain (NOD)-like receptors (NLRs) and cytoplasmic DNA sensors (3) . TLR9 detects non-methylated cytosine-guanosine (CpG) motifs, which are under-represented in the mammalian genome and therefore serve to alert DC to the presence of bacterial or viral DNA (3, 4) . Synthetic CpG oligonucleotide (ODN) agonists for TLR9 have therapeutic applications and consequently have been extensively characterized (5, 6) . They come in several classes, differing in their nucleotide sequence, their single or double stranded nature, their CpG content and their degree of stabilization by phosphorothioation (6) . Each class of CpG ODN differs somewhat in its biological outcome, which in part is determined by the cell types they activate and their trafficking within the endosomal network (7) . Phase I/II clinical trial have focused on the use of class B ODN (B-ODN) (5) , which are single stranded, fully phosphorothioated and induce B cell proliferation, plasmacytoid DC (pDC) maturation, and in the mouse, maturation of conventional DC. The phosphorothioate backbone not only confers resistance to nuclease degradation, but also increases ODN uptake (8, 9) , increases affinity for TLR9 and alters the sequence specificity for TLR9-mediated responses (9) (10) (11) . The optimized B-ODN sequences for the stimulation of mice and humans are different. However, this species sequence specificity is not seen with natural phosphodiester DNA (11) , and these phosphorothioate-specific sequence effects could act either at the level of ODN uptake or TLR9 binding.
The immunogenicity of B-ODN has been extensively documented in mouse experimental models and B-ODN are now in phase I/II clinical trials as vaccine adjuvants to enhance immune responses against infectious diseases and cancer (5) .
Mechanistically, it is well established that activation by CpG ODN requires TLR9 (6) .
However, TLR9 resides in intracellular compartments (12) , so how inoculated CpG ODN gain access to TLR9 remains unclear. There is some evidence to implicate receptor(s) in their uptake (13) , including the natural killer cell Ig-like receptor KIR3DL2 (14) and CD14 (15) for some other cell types. Whether professional antigen presenting cells (APC) such as DC and B cells express unique receptors that facilitate uptake of CpG ODN has not been established. This is an important issue since presentation of vaccine antigens by these APC is critical for induction of T cell immunity and antibody production.
DEC-205 (CD205) is a 205 kDa molecule that has a cysteine-rich domain, a fibronectin type II domain and 10 C-type lectin-like domains, as well as an internalization sequence in its cytoplasmic tail (16, 17) . It is expressed at different levels on DC, B cells, T cells and thymic epithelial cells (18) . The function of DEC-205 is unknown, but it has endocytic capacity, recycles through late endosomal/lysosomal compartments (19) and facilitates antigen presentation when targeted with antigen-bearing monoclonal antibodies (20) . Furthermore, its domain structure suggests the potential for recognition of multiple ligands. These features have lent support to the hypothesis that DEC-205 may function as a "promiscuous" antigen receptor (16, 20) . However, its natural ligands are yet to be identified (21, 22 ).
Here we show that DEC-205 is a key receptor involved in the uptake of B-ODN, a clinically-relevant adjuvant, facilitating biological activities in DC and B cells. Our study also suggests that DEC-205 may dictate the species specificity of stimulatory ODN used in man. (Fig. 1A) . To directly assess whether DEC-205 on its own was able to bind CpG ODN, we generated recombinant soluble and measured binding to CpG ODN by ELISA. Indeed, DEC-205 but not three other control lectins (mDC-SIGN, Clec12A and Clec9A) bound CpG ODN 1668 (Fig. 1B,   C) . We further confirmed the capacity of DEC-205 but not Clec9A to bind CpG ODN by using surface plasmon resonance (SPR) (Fig. 1D-F) . To determine whether the CpG motif was critical for binding DEC-205, we compared binding of three class B ODN (1668, 1826, 2006 ) that contain the CpG motif to that of control counterparts in which the CpG motif was reversed to GpC (i.e. no CpG) so they cannot activate TLR9 (10) (Fig. 1G-I ). This revealed that the CpG motif was not necessary for binding DEC-205, despite its requirement for signalling via TLR9 (10). (Fig. 1K,L) . However mouse DEC-205 could bind class C ODN 2395, whereas human DEC-205 did so very poorly (Fig. 1K,L shown to be capable of using several KIR, including KIR3DL2, to capture and deliver CpG ODN to TLR9 in vitro (14) . Similarly, CD14 was shown to bind nucleic acid and shuttle it to TLR9 in macrophages (15) . The importance of CD14 in responding to CpG ODN in vivo was shown at the level of cytokine production, with CD14 -/-mice showing a decrease in their ability to produce IL-6, IL-8 and IL-1. However, direct uptake via CD14, which is expressed at low levels by DC, was not shown in vivo, questioning the precise mechanism by which this molecule influences CpG ODN uptake. Whether the observations for murine CD14 will also extend to human CD14 is Conflict-of-interest disclosure: The authors declare no competing financial interests. 
Results

Mouse and human DEC-205 bind CpG ODN
Materials and Methods
Mice
Fluorescent staining of DC and other cell types
Detailed information on mAb used and staining procedures have been described elsewhere (27, 28). DC were isolated as described previously (37). Briefly, spleens were chopped, digested with collagenase and DNAse at room temperature, and treated with EDTA. Low-density cells were obtained by density centrifugation (1.077 g/cm was also measure by ELISA using the eBioscience kit according to the manufacturer's instructions. For the induction of in vivo CTL, mice were immunised with 1 g of anti-Clec12A-OVA mAb in the presence or absence of 5 nmoles of CpG (1668). Six days later mice were injected with target cells and in vivo killing was determined as described elsewhere (27, 38).
Confocal microscopy
Mice were injected with 20 g 1668 CpG ODN-Cy3. Spleens were extracted 30 min later and DC isolated. CD8 + DC were further purified by flow cytometry. DC were placed on anti-MHC class II coated coverslips (1.5h at 37 o C), fixed for 30 min with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, stained with biotinylated mAb against MHC class II and Streptavidin-Alexa488, counterstained with 5 ug/ml DAPI and mounted using Prolong Gold Antifade Reagent (Invitrogen). .
Images were acquired on a LSM700 confocal microscope (Zeiss) and analysed using the Imaris software (Bitplane).
ELISA for the detection of DEC-205/CpG ODN interaction
ELISA plates (Costar, Broadway, Cambridge, UK) were coated overnight at 4 o C with 10 g/ml of specified mAb. Unbound mAb was washed away (PBS, 0.05% Tween-20) before proteins (diluted in PBS/3% BSA) were added (4 o C, overnight). Captured protein was exposed to various biotinylated CpG ODN at specified concentrations (2 h, room temperature), detected with SA-HRP (GE Healthcare, UK, 2h room temperature) and colorimetric reaction and visualised using ABTS (2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid). Each titration point was performed in duplicate.
Surface plasmon resonance (SPR)
Binding of DEC205 1668 CpG ODN was assessed using a Biacore 3000. Sensorgram data were plotted using BIAevaluation software and exported to Prism for further analysis.
Statistical Analysis
Unpaired t-test was performed on the data. The significance of differences is listed as follows: not significant (n/s), p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001. determined by a one-tailed unpaired student t-test. n/s not significant.
Analysis was performed in Prism (GraphPad Sofware, Inc
